Pharmateca

Фарматека

2073-40342414-9128

Bionika Media

312276

10.18565/pharmateca.2019.11.69-72

Articles

Статьи

Research Article

Some issues of methotrexate pneumonitis in rheumatoid arthritis

Некоторые вопросы метотрексатного пневмонита при ревматоидном артрите

Bestaev

D. V

Бестаев

Д. В

MD, Head of the Department of Internal Diseases № 3

д.м.н., зав. кафедрой внутренних болезней № 3

dayidbestaev@rambler.ru

Ktsoeva

S. A

Кцоева

С. А

Brtsieva

Z. S

Брциева

З. С

Khutieva

L. M

Хутиева

Л. М

Osipova

L. V

Осипова

Л. В

Burduli

N. N

Бурдули

Н. Н

Kotsoeva

O. T

Коцоева

О. Т

Bestaeva

T. D

Бестаева

Т. Д

North Ossetian State Medical AcademyСеверо-Осетинская государственная медицинская академия

Family Medicine ClinicКлиника «Семейная медицина»

20102019

2611

VOL 26, NO11 (2019)

ТОМ 26, №11 (2019)

697203032023

2019

Bionika Media

ООО «Бионика Медиа»

https://journals.eco-vector.com/2073-4034/article/view/312276

Rheumatoid arthritis (RA) is a systemic autoimmune rheumatic disease with a wide range of extraarticular manifestations along with joint damage. Extraarticular manifestations of RA include pulmonary pathology (PP). The development of PP in patients with RA can by directly influenced by the course of the disease, infection, as well as therapy with disease-modifying antirheumatic drugs (DMARDs). The “gold" standard for RA therapy includes treatment with methotrexate. The article provides an overview of recent studies in the field of studying the role of methotrexate in the development of PP in patients with RA.

Ревматоидный артрит (РА) - системное аутоиммунное ревматическое заболевание, при котором наряду с поражением суставов отмечается широкий спектр экстраартикулярных проявлений. К внесуставным проявлениям (РА) относится легочная патология (ЛП). На развитие ЛП у больных РА могут влиять непосредственно течение заболевания, инфекция, а также терапия базисными противовоспалительными препаратами. В «золотой» стандарт терапии РА входит лечение метотрексатом. В статье представлен обзор результатов исследований последних лет в области изучения роли метотрексата в развитии ЛП у больных РА.

rheumatoid arthritismethotrexatepulmonary pathology

ревматоидный артритметотрексатлегочная патология

Насонов Е.Л., Насоновa В.А. Ревматология: Национальное руководство М., 2008.

Caporali R., Cavagna L., Montecucco C. Pain in arthritis. Eur J. Pain. 2009;3(Suppl. 2):123-27. Doi: 10.1016/j.eujps.2009.07.009

Govoni M., Caporali R. Predicting and managing the progression of structural damage in rheumatoid arthritis: where do we stand? Clin Exp Rheumatol. 2012;30(4):459-63.

Krishnan E., Lingala B., Bruce B., Fries J.F. Disability in rheumatoid arthritis in the era of biological treatments. Ann Rheum Dis. 2012;71(4):213 18. Doi: 10.1136/annrheumdis2011-200354

Gabriel S.E., Crowson C.S., Kremers H.M., et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthr Rheum. 2003;48(1):54-8. Doi: 10.1002/art.10705.

Cimmino M.A., Salvarani C., Macchioni P, et al. Extra-articular manifestations in 587 Italian patients with rheumatoid arthritis. Rheumatol Int. 2000;19(6):213-17. Doi: 10.1007/ PL00006853.

Cavagna L., Boffini N., Cagnotto G., et al. Atherosclerosis and rheumatoid arthritis: more than a simple association. Mediators Inflamm. 2012;2012:147354. Doi: 10.1155/2012/147354.

Turesson C. Extra-articular rheumatoid arthritis. Curr Opin Rheumatol. 2013;25(3):360-66. Doi: W.W97/BOR.0b013e32835f693f.

Gauhar U.A., Gaffo A.L., Alarcon G.S. Pulmonary manifestations of rheumatoid arthritis. Semin Respir Crit Care Med. 2007;28(4):430-40. Doi: 10.1055/s-2007-985664.

10.

Young A, Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best practice and research. Clin Rheumatol. 2007;21(5):907-27. Doi: 10.1016/j. berh.2007.05.007.

11.

De Lauretis A., Veeraraghavan S., Renzoni E. Connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis. 2011;8(1):53-82. Doi: 10.1177/1479972310393758.

12.

Ellman P., Ball R. Rheumatoid arthritis with joint and pulmonary manifestations. Br Med J. 1948;2(4583):816-20. Doi: 10.1136/ bmj.2.4583.816.

13.

Бестаев Д.В., Каратеев Д.Е., Насонов Е.Л. Интерстициальное поражение легких у больных ревматоидным артритом в эру применения генно-инженерных биологических препаратов. Клиническая фармакология и терапия. 2013;22(1):55-61.

14.

Kim E.J., Elicker B.M., Maldonado F., et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35(6): 1322-28. Doi: 10.1183/09031936.00092309.

15.

Ascherman D.P. Interstitial lung disease in rheumatoid arthritis. Curr Rheumatol Rep. 2010;12(5):363-69. Doi: 10.1007/s11926-010-0116-z.

16.

Hunninghake G.W., Fauci A.S. Pulmonary involvement in the collagen vascular diseases. Am Rev Respir Dis. 1979;119(3):471-503. Doi: 10.1164/arrd.1979.119.3.471.

17.

Cervantes-Perez P., Toro-Perez A.H., Rodriguez-Jurado P. Pulmonary involvement in rheumatoid arthritis. J. Am Med Association. 1980;243(17):1715-19. Doi: 10.1001/ jama.243.17.1715.

18.

Mori S., Koga Y., Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med. 2012;106(11):1591-99. Doi: 10.1016/j. rmed.2012.07.006.

19.

Saag K.G., Kolluri S., Koehnke R.K., et al. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthr Rheum. 1996;39(10):1711-19. Doi: 10.1002/ art.1780391014.

20.

Koduri G., Norton S., Young A., et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatol. (Oxford). 2010;49(8): 1483-89. Doi: 10.1093/rheumatology/keq035.

21.

Bongartz T., Nannini C., Medina-Velasquez Y.F., et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis - a population-based study. Arthr Rheum. 2010;62(6):1583-91. Doi: 10.1002/art.27405.

22.

Toyoshima M., Chida K., Suda T., Sato M. Methotrexate might increase mortality from interstitial lung disease in rheumatoid arthritis. Am J Respir Crit Care Med. 2012;185(9):1024. Doi: 10.1164/ajrccm.185.9.1024.

23.

Inokuma S. Leflunomide-induced interstitial pneumonitis might be a representative of disease-modifying antirheumatic druginduced lung injury. Exp Opin Drug Safety 2011;10(4):603-11. Doi: 10.1517/14740338.2011.560835.

24.

Perez-Alvarez R., Perez-de-Lis M., Diaz-Lagares C., et al. interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthr Rheum. 2011;41(2):256-64. Doi: 10.1016/j.semarthrit 2010.11.002.

25.

Panopoulos S.T., Sfikakis PP Biological treatments and connective tissue disease associated interstitial lung disease. Curr Opin Pulm Med. 2011;17(5):362-67. Doi: 10.1097/ MCP0b013e3283483ea5.

26.

Acute lymphocytic leukemia in children: maintenance therapy with methotrexate administered intermittently. Acute leukemia Group B. JAMA. 1969;207(5):923-28. Doi: 10.1001/ jama.1969.03150180053011.

27.

Engelbrecht J.A., Calhonn S.L., Scherrer J.J. Methotrexate pneumonitis after low-dose therapy for rheumatoid arthritis. Arthr Rheum. 1983;26:1275-78. Doi: 10.1002/ art.1780261016.

28.

Imokawa S., Colby T.V., Leslie K.O., Helmers R.A. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J. 2000;15:373-81.

29.

Salliot C., van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009;68:1100-104. Doi: 10.1136/ard.2008.093690.

30.

Kinder A.J., Hassell A.B., Brand J., et al. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatol. (0xford).2005;44:61-6. Doi: 10.1093/rheumatology/keh512.

31.

Conway R., Low C., Cotighian R.J., et al. Methotrexate and interstitial lung disease in rheumatoid arthritis a systematic literature review and meta-analysis. Arthr Rheum. 2012;64:5918. Doi: 10.1002/art.38322.

32.

Alarcon G.S, Kremer J.M., Macaluso M., et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med. 1997;127:356-64. Doi: 10.7326/0003-4819-127-5-199709010 00003.

33.

Bedrossian C.W., Miller W.C., Luna M.A. Methotrexate-induced diffuse interstitial pulmonary fibrosis. South Med J. 1979;72:313 18. Doi: 10.1097/00007611-197903000 00023

34.

Cannon G.W, Ward J.R., Clegg D.O., et al. Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis. Arthr Rheum. 1983;26:269-74. Doi: 10.1002/art.1780261015.

35.

Collins K, Aspey H., Todd A., et al. Methotrexate pneumonitis precipitated by switching from oral to parenteral administration. Rheumatol. (Oxford). 2008;47:109-10. Doi: 10.1093/rheumatology/ kem230.

36.

Barrera P., van Ede A.E., Laan R.F., et al. Methotrexate-related pulmonary complications in patients with rheumatoid arthritis; cluster of five cases in a period of three months. Ann Rheum Dis. 1994;53:479-30. Doi: 10.1136/ ard.53.7.479.

37.

Kremer J.M., Alarcon G.S., Weinblatt M.E., et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-assonated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthr Rheum. 1997;40:1829-37. Doi: 10.1002/ art.1780401016.

38.

van der Veen M.J., Dekker J.J., Dmant H.J., et al. Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. J Rheumatol. 1995;22:1766-68.

39.

Dawson J.K., Graham D.R., Desmond J., et al. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatol. (0xford).2002;41:262-67. Doi: 10.1093/ rheumatology/41.3.262.

40.

Beyeler C., Jordi B., Gerber N.J., ImHof V. Pulmonary function in rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. Br J Rheumatol. 1996;35:446-52.

41.

Cottin V, Tebib J., Massonnet B., et al. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest. 1996;109:933-38. Doi: 10.1378/chest.109.4.933.

42.

Cook N.J., Carroll G.J. Successful reintroduction of methotrexate after pneumonitis in two patients with rheumatoid arthritis. Ann Rheum Dis. 1992;51:272-74. Doi: 10.1136/ard.51.2.272.

43.

Khadadah M.E., Jayakrishnan B., AI-Gorair S., et al. Effect of methotrexate on pulmonary function in patients with rheumatoid arthritis a prospective study. Rheumatol. 2002;22:204-7. Doi: 10.1007/s00296-002-0227-6.

44.

Iikuni N., Kitahama M., Ohta S., et al. Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease. Mod Rheumatol. 2006;16(5):282-88. Doi: 10.1007/ s10165-006-0502-6.

45.

Hsu PC., Lan J.L. Hsieh T.Y, et al. Methotrexate pneumonitis in a patient with rheumatoid arthritis. J Microbiol Immunol Infect. 2003;36:137-40.

46.

Arakawa H., Yamasaki M., Kurihara Y., et al. Methotrexate-induced pulmonary injury: serial CT findings. J Thorac Imaging. 2003;18(4):231-36.

47.

Ohosone Y, Okano Y, Kameda H., et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol. 1997;24(12):2299-303.

48.

Lateef O., Shakoor N., Balk K.A. Methotrexate pulmonary toxicity. Expert Opin Drug Saf. 2005;4(4):723-30. Doi: 10.1517/14740338.4.4.723.

49.

Leduc D., De Vuyst P., Lheureux P., et al. Pneumonitis complicating low-dose methotrexate therapy for rheumatoid arthritis. Discrepancies between lung biopsy and bronchoalveolar lavage findings. Chest. 1993; 104(5): 1620-23. Doi: 10.1378/ chest.104.5.1620.

50.

Golden M.R., Katz R.S., Balk R., Golden H.E. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol. 1995;22(6):1043-47.

51.

Carson C.W, Cannon G.W., Egger M.J., et al. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthr Rheum. 1987;16(3):186-95.